Sou Hu Cai Jing·2026-01-31 02:47Core Insights - The article discusses the tragic story of Zhao Ning, a prominent figure in the pharmaceutical industry, who despite her wealth and control over two publicly listed companies with a market value of 370 billion yuan, could not overcome her battle with cancer [1][2]. Company Overview - Zhao Ning co-founded WuXi AppTec and WuXi Biologics, which together hold a significant market value of 370 billion yuan and dominate the research and development landscape for top global pharmaceutical companies [1]. - The companies have played a crucial role in elevating China's pharmaceutical research capabilities to international standards, providing affordable medications to the public [12]. Industry Context - The narrative highlights the challenges faced by the pharmaceutical industry in China during the early 2000s, where there was a lack of domestic drug approval standards and a heavy reliance on imported medications [3][6]. - Zhao Ning and her partner made a strategic decision to pivot towards Contract Research Organization (CRO) services, allowing them to gain valuable insights and expertise from leading global pharmaceutical companies [7]. Personal Journey - Zhao Ning's personal struggle with cancer spanned 20 years, during which she managed to build a successful business while undergoing treatment [9]. - Despite her health challenges, she remained actively involved in the operations of her companies, demonstrating resilience and dedication to her work [9][10]. Legacy - Zhao Ning left behind a significant educational fund of 100 million yuan for her alma mater, Peking University, symbolizing her commitment to advancing education and research in the field [11]. - Her legacy is marked by the impact she had on the pharmaceutical industry in China, enabling many citizens to access life-saving medications, despite her inability to save herself [12].